Three combinations of targeted therapy with BRAF/MEK inhibitors have received FDA approval in the unresectable setting (dabrafenib and trametinib; vemurafenib and cobimetinib; encorafenib and binimetinib), while dabrafenib and trametinib are also approved as adjuvant therapy following the resection of stage III/IV melanoma. This evidence concerns the gene MAP2K7 and melanoma.